Product Description
Novel Activin & GDF Ligand Trap for the Treatment of Pulmonary Hypertension. (Sourced from: https://erj.ersjournals.com/content/60/suppl_66/3238#:~:text=Aims%20and%20objectives%3A%20HS135%20is,traps%20such%20as%20ActRIIA%2DFc.)
Mechanisms of Action: ActR Inhibitor
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 35Pharma Inc
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HS135-002 | P1 |
Not yet recruiting |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2026-02-01 |